<DOC>
	<DOCNO>NCT02828618</DOCNO>
	<brief_summary>This study consist three part , whereas Part 1 Part 2 perform Germany , Part 3 multinational trial . All patient suspicion advance ovarian cancer detect participate study center pre-screening . The study center register patient suspected ovarian cancer screen log . After patient give informed consent , enrol different part study . TRUST-Trial : This part compare two strategy therapy advanced ovarian cancer . En detail , part trial evaluate one two strategy time surgery within therapeutic procedure may show significant advance term overall survival .</brief_summary>
	<brief_title>Trial Radical Upfront Surgery Advanced Ovarian Cancer</brief_title>
	<detailed_description>Both randomise group treat surgery complete resection follow guideline recommendation include median laparotomy , complete adhesiolysis , hysterectomy , bilateral salpingo-oophorectomy , omentectomy ( partial ) resection affect organ ( e.g . small large bowel , peritoneum , spleen , pancreas , peritoneum , urinary tract etc . ) well pelvic paraaortic lymphadenectomy indicate . Patients significant pleural effusion ( &gt; 500 mL right chest pleural effusion leave chest , assess either ultrasound CT scan ) need undergo video assist thoracoscopy open assessment pleura prior debulking surgery detect possible remove intrathoracic disease . Group 1 : Primary debulking surgery Patients allocate primary debulking group undergo surgery follow 6 cycle platinum taxane base chemotherapy . Recommended systemic treatment Group 1 : It recommend start systemic treatment sufficient regeneration surgery [ 45 ] , ideally 2 6 week ( late 8 week ) surgery . The following treatment recommend : 1 . Participation prospective randomize trial , long participation possible case randomization either arm current study 2 . Carboplatin AUC 5-6 / paclitaxel 175 mg/m² q21 / bevacizumab 15mg/KG q21 , 6 cycle follow bevacizumab maintenance therapy total 15 month disease progression . 3 . Carboplatin AUC 5-6 / paclitaxel 175 mg/m² q21 , 6 cycle . Substitution paclitaxel docetaxel ( 75mg/m² ) case contraindication paclitaxel possible . Maintenance/consolidation therapy inside prospective trial accord national standard treatment allow . Additional treatment outside prospective study recommend . 4 . Carboplatin AUC 5 - 6 , q21 , 6 cycle case contraindication combination chemotherapy Group 2 : Interval debulking surgery Patients allocate interval debulking surgery group undergo biopsy confirm ovarian cancer 3 cycle neoadjuvant preoperative platinum taxane base chemotherapy . Then interval debulking surgery perform follow 3 cycle postoperative platinum taxane base chemotherapy Recommended systemic treatment Group 2 : It recommend start systemic treatment soon possible biopsy confirmation ovarian cancer . The following treatment recommend neoadjuvant chemotherapy : 1 . Participation prospective randomize trial , long participation possible case randomization either arm current study 2 . Carboplatin AUC5-6 / paclitaxel 175 mg/m² q21 , 3 cycle . Substitution paclitaxel docetaxel ( 75mg/m² ) case contraindication paclitaxel possible . 3 . Carboplatin AUC 5-6 , q21 , 3 cycle case contraindication combination chemotherapy It recommend start postoperative chemotherapy sufficient regeneration interval debulking surgery , ideally 2 6 week surgery . The following treatment recommend : 1 . Participation prospective randomize trial , long participation possible case randomization either arm current study 2 . Carboplatin AUC 5-6 / paclitaxel 175 mg/m² q21 / bevacizumab 15mg/KG q21 , 3 cycle follow bevacizumab maintenance therapy total 15 month disease progression . 3 . Carboplatin AUC5-6 / paclitaxel 175 mg/m² q21 , 3 cycle . Substitution paclitaxel docetaxel ( 75mg/m² ) case contraindication paclitaxel possible . Maintenance/consolidation therapy inside prospective trial accord national standard treatment allow . Additional treatment outside prospective study recommend . 4 . Carboplatin AUC 5-6 , q21 , 3 cycle case contraindication combination chemotherapy</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>suspect histologically confirm , newly diagnose invasive epithelial ovarian cancer FIGO stage IIIBIV ( IV resectable metastasis ) Females age ≥ 18 year Patients give write informed consent Good performance status ( ECOG 0/1 ) Good ASA score ( 1/2 ) Preoperative CA 125/CEA ratio ≥ 25 ( CA125 elevate ) * If &lt; 25 and/or biopsy nonserous , nonendometroid histology , esophagogastroduodenoscopy ( EGD ) colonoscopy mandatory exclude gastrointestinal primary cancer Assessment experience surgeon , base available information , patient undergo procedure tumor potentially completely resected Adequate bone marrow function : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L . This ANC induce support granulocyte colony stimulate factor . Platelet count ≥ 100 x 109/L . Renal function : SerumCreatinine ≤ 1.5 x institutional upper limit normal ( ULN ) . Hepatic function : Bilirubin ≤ 1.5 x ULN . SGOT ≤ 3 x ULN Alkaline phosphatase ≤ 2.5 x ULN . Neurologic function : Neuropathy ( sensory motor ) less equal CTCAE Grade 1 . Non epithelial ovarian malignancy borderline tumor Secondary invasive neoplasm last 5 year ( except synchronal endometrial carcinoma FIGO IA G1/2 , non melanoma skin cancer , breast cancer T1 N0 M0 G1/2 ) sign relapse activity . Recurrent ovarian cancer Prior chemotherapy ovarian cancer abdominal/pelvic radiotherapy Unresectable parenchymal lung metastasis , liver metastasis bulky lymphnodes mediastinum CT chest abdomen/pelvis Clinical relevant dysfunction blood clotting ( include drug induce ) Any significant medical reason , age performance status allow perform study procedure ( estimation investigator ) Pregnancy Dementia significantly alter mental status would prohibit understanding give informed consent Any reason interfere regular followup</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>